Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: An arrangement for generating electricity including thermoelectric generators, the generators converting a heat difference between a first and a second surface of a generator in electricity, elements to provide a heated first medium to the first surfaces of the one or more thermoelectric generators and elements to provide a second medium with a temperature lower than that of the first medium to the second surfaces of the one or more thermoelectric generators. The first medium is heated by solar energy collector elements, which solar energy collector elements transfer collected solar energy to air passing through the solar energy collector elements. The first medium is a working fluid or the heated air itself. The second medium is a working fluid or ambient air with a lower temperature than the first medium.

Abstract: Gloves and methods of manufacturing gloves that provide structural support elements to prevent or minimize glove roll, and that alternatively or in addition provide protection against blunt force to the back of the hand, including methods of manufacture, specifically including molding or screening the structural support elements and/or protective cushions to the back of the hand side of the glove.

Abstract: A port-centric controller system for a computer including a plurality of network ports implemented with a plurality of network controllers and a driver system capable of operating each of the network ports in either a stand-alone mode or a team mode and that monitors the status of each of the network ports. The controller system further includes configuration logic that interfaces the driver system to display port-specific graphic representations of the configuration and status of each of the plurality of network ports. The graphic representations preferably distinguish between each of the plurality of network controllers and each of the plurality of network ports. The driver system monitors the link status of each of the network ports indicative of cable status, and the graphic representations include a corresponding cable fault icon indicative of a cable fault at a network port.